NOTE: FAQ refers to Lyme disease
Supportive Oligonucleotide Therapy (SOT)
The simple description is the Q-REstrain is an autologous (derived from and unique to each individual patient) therapy which is based on RNA interference technology. The RGCC lab can identify the specific gene sequences of different targets such as cancer, Lyme, and various viruses and take advantage of oligonucleotide molecules (microRNAs isolated in the patient’s blood sample) which contribute to gene silencing of these specific genes. It is best described as a gene silencing technology.
The more technical description is the Q-REstrain consists of microRNA molecules with the ability to regulate the gene expression of a specific target. The short dsRNAs (double-stranded RNAs) are derived by cleavage of long dsRNA from Dicer and can be microRNAs (miRNAs). miRNAs then assemble with RNA-induced silencing complex (RISC) and cause gene silencing. RNAi has been used in the therapy of different diseases including cancer, viral infections, respiratory diseases, etc. Targeting of specific proteins, through degradation of their mRNA, is very common in treatment of different types of cancer or other infections. Q-REstrain contains microRNAs isolated by the patient’s sample, leading to the degradation of specific mRNA molecules, which are overexpressed in this specific sample (due to active infection), thus regulating the expression. Q-REstrain is for autologous use only, meaning each therapy is derived 100% from the sample submitted by the patient, not from an outside library of RNA or DNA.
It has been observed that the genes coding for replication of a microbe or cancer cell, which are the treatment targets, vary from person to person, as the DNA of the microbe is influenced by the environment within the body and are unique to the individual and the infections they carry. It is well known that microbes can share genetic information to develop resistance to medications. Q-Restrain from RGCC overcomes this hurdle by expanding cell lines and microbial lines with advanced technology, isolating the exact gene sequence as it exists in the individual patient. Brilliant science.
THE technology used to isolate the pathogen
The technology utilized to isolate the necessary genetic material to create the Q-REstrain is a PCR analysis that evaluates both the cells and the serum. This evaluation is looking for active infections (actively replicating). The lab isolates the white blood cells using gradient Ficoll with a membrane that isolates white cells from platelets and red blood cells. The PCR technique is used with primers for different species of Borrelia, Babesia and Bartonella and many more pathogens. Positive and negative controls are used in all reactions.
What Q-Restrain made of
The therapy contains autologous (derived from the patient’s blood) oligonucleotide molecules (microRNAs) isolated by the patient’s sample, which contribute to silencing of specific, target genes that have to do with microbial replication. When the microbe can not replicate, it will, in time, die out.
FAQ's
You must be off all therapies for 14 days prior to blood draw for the Q-REstrain and again 7-14 days prior to the actual infusion.
All therapies may be resumed (as outlined above) 7 days after infusion.
The Q-REstrain targets only a specific region of a gene. If a patient has multiple active infections, then multiple Q-REstrain treatments will be needed. One for each infection since each target has its own unique DNA sequence.
There is no protein in Q-REstrain. The Q-REstrain is autologous microRNAs molecules, which are used to block the messenger RNA (mRNA), therefore they block the peptide synthesis.
While Q-REstrain is well tolerated, when dealing with living pathogens in a human body there are potential side effects even with a gene silencing therapy like Q-REstrain. Some of the common side effects we’ve seen have been:
- Headaches
- Increased fatigue
- Flu-like symptoms
- In Lyme or viral - co-infections can flare
The lab reports improvements of ~95% in the case of Lyme, Babesia and Bartonella, ~92% in the case of viral infections, and ~78% in cancer cases provided that the repeated testing and treatment protocols are observed.
Important: Percentages provided above are in-lab numbers only. The wording “Positive Clinical Outcome,” which most define as a “success rate” is actually defined by the lab as a complete or partial response, or stabilization of the disease. This means “success” is any positive response, not eradication, although a complete response for some will mean eradication for others, it may mean progress, but the patient’s cancer or viral/Lyme load and symptoms may not get any better.
- Not suitable for children under 5 years (Lyme & virus) or 11 (cancer)
- Contraindicated during pregnancy or recent blood transfusion
- Certain concurrent treatments may affect eligibility
- Consult with the clinic about other possible contraindications
For Lyme/Virus patients
- Positive serum or whole blood results from reputable laboratory such as Igenex, Galaxy, TLab, MDL, Vibrant, Quest or LabCorp within 6 months
For cancer patients
- Oncotrace or other RGCC test within 6 months
- Consult with RGCC certified provider such as our clinic.